aTyr Pharma Q3 2026 net loss narrows 29% to $18.26 million

PUBT · 1d ago
aTyr Pharma Q3 2026 net loss narrows 29% to $18.26 million
  • aTyr Pharma’s third-quarter 2026 net loss attributable to shareholders narrowed 29% year over year to $18.26 million.
  • Total revenue fell to none from $190,000 a year earlier, while operating expenses dropped 30% to $18.79 million.
  • Cash and investments totaled $50.3 million at September 30, supporting projected operations into late 2028 under current plans.
  • FDA protocol alignment cleared the way for initial Phase 3 efzofitimod study activities; strategic partnerships remain the priority for advancing development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9870838) on November 05, 2026, and is solely responsible for the information contained therein.